OverviewChartNewsTraderScreen

UBS Knock-Out LLY/  DE000UM0C494  /

Frankfurt Zert./UBS
10/11/2024  8:29:03 AM Chg.-0.140 Bid9:08:43 AM Ask9:08:43 AM Underlying Strike price Expiration date Option type
25.420EUR -0.55% 25.480
Bid Size: 1,000		 25.850
Ask Size: 1,000		 Eli Lilly and Co 632.423 USD 12/31/2078 Call
TeleTrader 10/2 Eli Lilly to commit $4.5 billion in a new Indiana facility
Newsfile Corp 9/16 Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
TeleTrader 9/9 Eli Lilly appoints Lucas Montarce as CFO
Newsfile Corp 8/28 The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire 8/27 Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2024 Corporate Membership...
GlobeNewswire 8/26 Eliem Therapeutics Announces Additions to its Leadership Team
GlobeNewswire 8/21 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 8/21 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 8/14 Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire 8/14 Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire 8/8 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 8/8 Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
TeleTrader 8/8 US opens higher with data, earnings in focus
GlobeNewswire 8/8 ProQR Announces Second Quarter 2024 Operating and Financial Results
TeleTrader 8/8 Eli Lilly's Q2 revenue jumps 36% to $11.3B
GlobeNewswire 8/8 Defiance Launches LLYX, the First 2X Leveraged Single-Stock ETF on Eli Lilly
GlobeNewswire 8/7 Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire 8/6 Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire 8/6 SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discov...
GlobeNewswire 8/2 Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire 8/1 Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire 8/1 COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives
GlobeNewswire 8/1 Compass Pathways announces second quarter 2024 financial results and business highlights
GlobeNewswire 7/31 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFC, HMNF, MORF on Behalf of Shareholders
GlobeNewswire 7/31 MORF Alert: Wohl & Fruchter LLP Files Class Action Lawsuit on Behalf of Shareholders of Morphic Hold...